BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum

Benzinga2021-07-19

BioNTech SE is buying a cell therapy R&D platform plus a manufacturing site from Gilead Science Inc'sGILD 0.91%Kite subsidiary.

The deal gives BioNTech Kite's R&D IP for its personalized solid tumor neoantigen T cell receptor (TCR) work and the manufacturing center in Gaithersburg, MD, which supplies the clinical trial product.

This program builds and further extends BioNTech's leadership in individualized neoantigen targeting programs such as BNT122 (iNeST) and BNT221 (NEOSTIM).

The acquired Gaithersburg facility will provide production capacity to support clinical trials in the U.S. and complement BioNTech's existing cell therapy manufacturing facility in Germany.

Financial terms were not disclosed.

Kite's new manufacturing facility in Frederick, MD, for commercial production of CAR T-cell therapy is not part of the purchase agreement.

Price Action: BNTX shares are up 0.86% at $233.46 during the market session on the last check Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
34